Patents by Inventor Ralf Hosse

Ralf Hosse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES BINDING TO CD3 and CD19
    Publication number: 20240132590
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: August 8, 2023
    Publication date: April 25, 2024
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Maria Valeria GONZALEZ NICOLINI, Ralf HOSSE, Alexander KNAUPP, Ekkehard MOESSNER, Wolfgang RICHTER, Halina TROCHANOWSKA, Pablo UMAÑA, Christian KLEIN, Inja WALDHAUER
  • Bispecific antibodies against CD3EPSILON and ROR1
    Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • PH-DEPENDENT MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20240092853
    Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lorenzo DEHO, Christian GASSNER, Sylvia HERTER, Thomas HOFER, Ralf HOSSE, Adrian HUGENMATTER, Christian KLEIN, Florian LIMANI, Ekkehard MOESSNER, Melanie OBBA, Bianca SCHERER, Pablo UMANA
  • Antibodies binding to NKG2D
    Publication number: 20240067734
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Guy GEORGES, Ralf HOSSE, Inja WALDHAUER, Christian KLEIN, Pablo UMANA
  • ANTIBODIES BINDING TO CD3
    Publication number: 20240042022
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 8, 2023
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • ANTI-CEA ANTIBODIES
    Publication number: 20230365711
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 16, 2023
    Applicant: Roche Glycart AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Bispecific HER2 antibodies and methods of use
    Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Antibodies binding to CD3 and CD19
    Patent number: 11780920
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: October 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • ANTIBODIES BINDING TO CD3
    Publication number: 20230277662
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: April 26, 2023
    Publication date: September 7, 2023
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
  • Bispecific antibody molecules binding to CD3 and TYRP-1
    Patent number: 11672858
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
  • Tumor-targeted agonistic CD28 antigen binding molecules
    Patent number: 11608376
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20230076791
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 25, 2022
    Publication date: March 9, 2023
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Bispecific antibody molecules binding to CD3 and EGFRvIII
    Patent number: 11591397
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: February 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
  • ANTI-FAP ANTIBODIES AND METHODS OF USE
    Publication number: 20220281995
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 8, 2022
    Applicant: Roche Glycart AG
    Inventors: Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMANA
  • FUSION OF AN ANTIBODY BINDING CEA AND 4-1BBL
    Publication number: 20220267464
    Abstract: The invention relates to new humanized CEA antibodies and to CEA targeting 4-1BBL trimer-containing antigen binding molecules comprising these CEA antibodies as well as their use in the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Thomas Hofer, Christian Klein, Ekkehard Moessner, Christina Claus, Ralf Hosse, Bianca Scherer, Pablo Umana
  • NOVEL IMMUNOCONJUGATES
    Publication number: 20220242971
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: September 27, 2021
    Publication date: August 4, 2022
    Applicant: Roche Glycart AG
    Inventors: Oliver AST, Peter BRUENKER, Thomas U. HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20220220224
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 14, 2022
    Inventors: Marina BACAC, Peter BRUENKER, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20220213224
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 9, 2021
    Publication date: July 7, 2022
    Inventors: Christian KLEIN, Ekkehard MOESSNER, Ralf HOSSE, Peter BRUENKER, Pablo UMANA, Christiane NEUMANN